<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04171037</url>
  </required_header>
  <id_info>
    <org_study_id>2019-0348</org_study_id>
    <secondary_id>NCI-2019-07291</secondary_id>
    <secondary_id>2019-0348</secondary_id>
    <nct_id>NCT04171037</nct_id>
  </id_info>
  <brief_title>Optiflow THRIVE for Delivery of Oxygen to Patients During Total Intravenous Anesthesia While Undergoing Radiology Procedures</brief_title>
  <official_title>A Pilot Study of FDA Approved Optiflowâ„¢ THRIVE Versus Standard Non-Rebreathers in Patients With Potential High Risk of Airway Obstruction During Total Intravenous Anesthesia (TIVA) While Undergoing Interventional Radiology Procedures</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial studies how well Optiflow THRIVE works in delivering oxygen to patients during&#xD;
      total intravenous anesthesia while undergoing radiology procedures. The Optiflow THRIVE is an&#xD;
      oxygen administration device that delivers high-flow and humidified oxygen through the nose.&#xD;
      The Optiflow THRIVE device may improve oxygen delivery and reduce breathing complications.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVE:&#xD;
&#xD;
      I. To investigate the performance of Optiflow THRIVE relative to Standard Non-Rebreathers in&#xD;
      patients with high risk of difficult airway management undergoing interventional radiology&#xD;
      procedures for the planning of future clinical studies.&#xD;
&#xD;
      SECONDARY OBJECTIVE:&#xD;
&#xD;
      I. To describe the episodes of hypoxia (defined by peripheral capillary oxygen saturation&#xD;
      [SpO2] less than or equal to 92%) and the episodes of airway support which include: jaw&#xD;
      thrust, chin lift or insertion of an airway supporting device, such as oral/nasal airway or&#xD;
      supra airway device in order to recover the level of oxygenation above 92% associated with&#xD;
      Optiflow THRIVE.&#xD;
&#xD;
      OUTLINE: Patients are randomized to 1 of 2 arms.&#xD;
&#xD;
      ARM I: Patients receive 100% oxygen at a high flow rate via Optiflow THRIVE over 3 minutes&#xD;
      prior to anesthetic induction and at a higher flow rate until the end of procedure.&#xD;
&#xD;
      ARM II: Patients receive 100% oxygen at a lower flow rate via non-rebreather mask over 3&#xD;
      minutes prior to anesthetic induction and maintain the same flow rate until the end of&#xD;
      procedure.&#xD;
&#xD;
      After completion of study, patients are followed up at 15 minutes.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 4, 2019</start_date>
  <completion_date type="Anticipated">September 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total length of desaturation episodes (ToLDE) time (in minutes)</measure>
    <time_frame>During a fixed 60-minute observation window during total intravenous anesthesia (TIVA)</time_frame>
    <description>Desaturation episodes are characterized by the occurrence of hypoxia (defined by peripheral capillary oxygen saturation [SpO2] less than or equal to 92%).</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Obstructive Sleep Apnea</condition>
  <arm_group>
    <arm_group_label>Arm I (oxygen via Optiflow THRIVE)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive 100% oxygen at a high flow rate via Optiflow THRIVE over 3 minutes prior to anesthetic induction and at a higher flow rate until the end of procedure.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II (oxygen via non-rebreather mask)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients receive 100% oxygen at a lower flow rate via non-rebreather mask over 3 minutes prior to anesthetic induction and maintain the same flow rate until the end of procedure.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Oxygen Therapy</intervention_name>
    <description>Receive oxygen via Optiflow THRIVE</description>
    <arm_group_label>Arm I (oxygen via Optiflow THRIVE)</arm_group_label>
    <other_name>supplemental oxygen therapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Oxygen Therapy</intervention_name>
    <description>Receive oxygen via non-rebreather</description>
    <arm_group_label>Arm II (oxygen via non-rebreather mask)</arm_group_label>
    <other_name>supplemental oxygen therapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Questionnaire Administration</intervention_name>
    <description>Ancillary studies</description>
    <arm_group_label>Arm I (oxygen via Optiflow THRIVE)</arm_group_label>
    <arm_group_label>Arm II (oxygen via non-rebreather mask)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Optiflow THRIVE</intervention_name>
    <description>Oxygen Administration</description>
    <arm_group_label>Arm I (oxygen via Optiflow THRIVE)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Signed consent for the study&#xD;
&#xD;
          -  Patients with an SpO2 greater than or equal to 95% while breathing room air&#xD;
&#xD;
          -  Patients requiring total intravenous anesthesia (TIVA) but not tracheal intubation&#xD;
             during the proposed procedure - PLUS, any of the 2 following criteria: Body mass index&#xD;
             (BMI) greater than or equal to 32 kg/m^2, or neck circumference greater than or equal&#xD;
             to 43 cm in a male and 41 cm in a female, or has been diagnosed with moderate to&#xD;
             severe obstructive sleep apnea (OSA) with/without using a continuous positive airway&#xD;
             pressure (CPAP) device&#xD;
&#xD;
          -  Full course head and neck radiotherapy less than or equal to 6 months (the peak onset&#xD;
             time of acute facial and airway edema)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Significant pulmonary disease requiring supplemental oxygen in daily life (severe&#xD;
             pulmonary fibrosis, severe chronic obstructive pulmonary disease, etc.)&#xD;
&#xD;
          -  Significant cardiac disease (including history of myocardial infarction [MI] with&#xD;
             concurrent evidence of ischemic myocardial damage at the event, cardiomyopathy with&#xD;
             impaired left ventricular ejection fraction to less than 50% or uncompensated&#xD;
             congestive heart failure)&#xD;
&#xD;
          -  TIVA is contraindicate or having a proposed procedure without TIVA&#xD;
&#xD;
          -  Endotracheal intubation is required&#xD;
&#xD;
          -  American Society of Anesthesiologists (ASA) physical status classification 5&#xD;
&#xD;
          -  Patients who are non-English speaking&#xD;
&#xD;
          -  Emergency procedures&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gang Zheng</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gang Zheng</last_name>
    <phone>713-563-0117</phone>
    <email>gzheng@mdanderson.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>M D Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gang Zheng</last_name>
      <phone>713-563-0117</phone>
    </contact>
    <investigator>
      <last_name>Gang Zheng</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>M D Anderson Cancer Center website</description>
  </link>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 19, 2019</study_first_submitted>
  <study_first_submitted_qc>November 19, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 20, 2019</study_first_posted>
  <last_update_submitted>November 16, 2021</last_update_submitted>
  <last_update_submitted_qc>November 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sleep Apnea, Obstructive</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

